Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07535632) titled 'SBRT Followed by PD-1 Inhibitor, Bevacizumab and TAS-102 as Third-Line Therapy for Recurrent/Metastatic Colorectal Cancer' on April 10.

Study Type: Interventional

Study Design: Allocation: Randomized. Intervention model: Parallel Assignment. Primary purpose: Treatment. Masking: None (Open Label).

Primary Sponsor: Shanghai Zhongshan Hospital

Condition: Colorectal Neoplasms

Intervention: Radiation: SBRT Drug: Sintilimab Drug: Bevacizumab Drug: Trifluridine and Tipiracil Tablets

Recruitment Status: Not recruiting

Phase: Phase 2

Date of First Enrollment: June 1, 2026

Target Sample Size: 58

Countries of Re...